RVMD logo

RVMD Revolution Medicines Inc

$206.41
$0.52
(0.25%)
Today
45

Neutral Sentiment

How do you feel about RVMD?

Loading...
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034 KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034PR NewswireSAN DIEGO, Sept. 28, 2026 SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Equity Insider News Commentary- For most of the last four decades, RAS was the target oncology...
PR Newswire
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Key PointsRevolution Medicines has just received good news around a drug meant to treat pancreatic cancer...
Nasdaq News: Markets
Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 33.5% on an annualized basis producing an average annual return of 45.32%. Currently, Revolution Medicines has a marketread more...
Benzinga
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAxsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments...
Nasdaq News: Markets
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
Key PointsRevolution Medicines validated its approach to treating certain cancers with a recent regulatory approval...
Nasdaq News: Markets
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?
Key PointsIt's a cancer medication with immense potential...
Nasdaq News: Markets
Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage
CEO Mark Goldsmith said discussions with insurers gave the company confidence that they understand the drug’s clinical value.
Stocktwits
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 preclinical pancreatic cancer data.read more...
Benzinga